Der var i CHMP ligeledes enighed om, at den ovenfor nævnte information med hensyn til langtidseffekten bør tilføjes i afsnit 5. 1 (Farmakodynamiske egenskaber) i produktresumeet (SPC).
The CHMP also agreed that the above-mentioned information with regards to long- term efficacy should be included in section 5.1 (Pharmacodynamic Properties) of the Summary of Product Characteristics (SPC).